- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05178238
Intestinal Microbiota of Patients Hospitalized With Sars-CoV-2 (MICRODIGCOV)
The study investigators hypothesize that SARS-Cov2 infection alters the composition of the digestive microbiota and its functionality, resulting in changes in intestinal permeability and consequently in microbial digestive translocation. These changes may correlate with the magnitude of the SARS-CoV-2 viral load in the gastrointestinal tract and may have an impact on the clinical manifestations and evolvability of COVID-19.
Study Overview
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Nîmes, France
- CHU de Nimes
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
All adult patients hospitalized in the Nimes University Hoptial with SARS-CoV-2 infection confirmed by RT-PCR
Description
Inclusion Criteria:
- patient hospitalized at in Nimes University hospital
- Infection with SARS-CoV-2 confirmed by RT-PCR
- The patient must have signed the consent form
- The patient must be a member or beneficiary of a health insurance plan
Exclusion Criteria:
- The subject is participating in an interventional study susceptible to modify the intestinal microbiota, or is in a period of exclusion determined by a previous study
- It is impossible to give the subject informed information
- The patient is under safeguard of justice or state guardianship
- Patient with a chronic digestive pathology or having been operated in the previous year or having enteral nutrition or having had bariatric surgery
- Patient is pregnant, parturient or breastfeeding
Study Plan
How is the study designed?
Design Details
- Observational Models: CASE_ONLY
- Time Perspectives: PROSPECTIVE
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Patients with high viral load of SARS-CoV-2 in feces
|
Fecal sample taken to investigate intestinal microbiota |
|
Patients with low viral load of SARS-CoV-2 in feces
|
Fecal sample taken to investigate intestinal microbiota |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg)
Time Frame: Day 0
|
RT-qPCR of SARS-CoV-2 to calculate copies/mg |
Day 0
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Liver function tests of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg) if tested
Time Frame: Day 0
|
Day 0
|
|
|
Cytobacteriological urine exam of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg) if tested
Time Frame: Day 0
|
Day 0
|
|
|
Blood cultures of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg) if tested
Time Frame: Day 0
|
Day 0
|
|
|
Other infectious samples (other than SARS-CoV-2) of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg) if tested
Time Frame: Day 0
|
Day 0
|
|
|
Age of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg)
Time Frame: Day 0
|
Age in years |
Day 0
|
|
Sex of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg)
Time Frame: Day 0
|
Male/female |
Day 0
|
|
Clinical features of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg)
Time Frame: Day 0
|
Date of start of symptoms, current therapeutics, antibiotic therapy, blood pressure, heart rate, respiration rate, oxygen saturation, symptoms, Covid stage (ordinal 8 stage scale) |
Day 0
|
|
Total blood count of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg) if tested
Time Frame: Day 0
|
lymphocyte count, eosinophil count |
Day 0
|
|
C-reactive protein level biological data of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg) if tested
Time Frame: Day 0
|
concentration |
Day 0
|
|
Fibrinogen level of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg) if tested
Time Frame: Day 0
|
concentration |
Day 0
|
|
Lactate Dehydrogenase of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg) if tested
Time Frame: Day 0
|
concentration |
Day 0
|
|
D-dimer level of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg) if tested
Time Frame: Day 0
|
concentration |
Day 0
|
|
Ferritin levels, of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg) if tested
Time Frame: Day 0
|
Concentration |
Day 0
|
|
Albumin levels of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg)
Time Frame: Day 0
|
concentration |
Day 0
|
|
Calcium levels of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg) if tested
Time Frame: Day 0
|
concentration |
Day 0
|
|
Glomerular filtration rate of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg) if tested
Time Frame: Day 0
|
volume per time |
Day 0
|
|
Taxonomic features of intestinal microbiota of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg)
Time Frame: Day 0
|
Number of Operational Taxonomic Unit |
Day 0
|
|
Percentage of Operational Taxonomic Units in intestinal microbiota of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg)
Time Frame: Day 0
|
% |
Day 0
|
|
Diversity of intestinal microbiota of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg)
Time Frame: Day 0
|
Shannon Index |
Day 0
|
|
Diversity of intestinal microbiota of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg)
Time Frame: Day 0
|
Bray Curtis Index |
Day 0
|
|
LPS-binding Protein concentration of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg)
Time Frame: Day 0
|
pg/ml ELISA |
Day 0
|
|
soluble CD14 concentration of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg)
Time Frame: Day 0
|
ng/ml ELISA |
Day 0
|
|
RNA16s concentration of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg)
Time Frame: Day 0
|
PCR and sequencing |
Day 0
|
|
RNA18 concentration of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg)
Time Frame: Day 0
|
PCR and sequencing |
Day 0
|
|
I-FAB concentration of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg)
Time Frame: Day 0
|
ng/ml:ELISA |
Day 0
|
|
Claudin 3 concentration of patients with high viral load of SARS-CoV-2 in feces (>50 copies/mg) versus low viral load (≤50 copies/mg)
Time Frame: Day 0
|
ng/ml:ELISA |
Day 0
|
Collaborators and Investigators
Investigators
- Principal Investigator: Albert Sotto, CHU Nimes
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NIMAO/2021-1/AS-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.